Porter v. Pfizer, Inc.

Filing 16

MDL CONDITIONAL TRANSFERRING ORDER (CTO-7) TO THE USDC FOR THE DISTRICT OF CAROLINA (MDL 2502). Signed by Jeffrey N. Luthi for the MDL Panel on 3/19/14. (ysS, COURT STAFF) (Filed on 3/19/2014)

Download PDF
2:14-mn-02502-RMG Date Filed 03/19/14 Entry Number 31 Page 1 of 3 Case MDL No. 2502 Document 166 Filed 03/19/14 Page 1 of 3 UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION IN RE: LIPITOR (ATORVASTATIN CALCIUM) MARKETING, SALES PRACTICES AND PRODUCTS LIABILITY LITIGATION (NO. II) MDL No. 2502 (SEE ATTACHED SCHEDULE) CONDITIONAL TRANSFER ORDER (CTO −7) On February 18, 2014, the Panel transferred 42 civil action(s) to the United States District Court for the District of South Carolina for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. §1407. See _F.Supp.2d_ (J.P.M.L. 2014). Since that time, 198 additional action(s) have been transferred to the District of South Carolina. With the consent of that court, all such actions have been assigned to the Honorable Richard M Gergel. It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the District of South Carolina and assigned to Judge Gergel. Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. §1407 to the District of South Carolina for the reasons stated in the order of February 18, 2014, and, with the consent of that court, assigned to the Honorable Richard M Gergel. This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the District of South Carolina. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7−day period, the stay will be continued until further order of the Panel. FOR THE PANEL: Mar 19, 2014 Jeffery N. Lüthi Clerk of the Panel 2:14-mn-02502-RMG Date Filed 03/19/14 Entry Number 31 Page 2 of 3 Case MDL No. 2502 Document 166 Filed 03/19/14 Page 2 of 3 IN RE: LIPITOR (ATORVASTATIN CALCIUM) MARKETING, SALES PRACTICES AND PRODUCTS LIABILITY LITIGATION (NO. II) SCHEDULE CTO−7 − TAG−ALONG ACTIONS DIST DIV. C.A.NO. CASE CAPTION CALIFORNIA NORTHERN CAN CAN 3 3 14−00660 14−00736 Casanas v. Pfizer, Inc. Porter v. Pfizer, Inc. 3 14−00170 Spivey et al v. Pfizer Inc. 2 14−00067 Wright v. Pfizer Inc. CONNECTICUT CT IDAHO ID INDIANA SOUTHERN INS 1 14−00299 HAMILTON v. PFIZER, INC. 14−00070 Richeson v. Pfizer Inc IOWA SOUTHERN IAS 4 KENTUCKY EASTERN KYE 6 14−00025 Wyrick v. Pfizer Inc. LOUISIANA MIDDLE LAM 3 14−00128 Firmin v. Pfizer, Inc. NORTH CAROLINA EASTERN NCE 5 14−00024 Bass v. Pfizer Inc. 14−00401 Wallace v. Pfizer, Inc. OHIO NORTHERN OHN 1 MDL No. 2502 2:14-mn-02502-RMG Date Filed 03/19/14 Entry Number 31 Page 3 of 3 Case MDL No. 2502 Document 166 Filed 03/19/14 Page 3 of 3 WEST VIRGINIA NORTHERN WVN 5 14−00029 Stevey v. Pfizer Inc. WEST VIRGINIA SOUTHERN WVS WVS WVS WVS WVS WVS 2 2 2 2 2 2 14−10766 14−10900 14−10997 14−11054 14−11158 14−11170 Stoneking v. Pfizer, Inc. Sayre v. Pfizer Inc. Goodson v. Pfizer Inc. Good v. Pfizer Inc. Given v. Pfizer Inc. Olson v. Pfizer Inc.

Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.


Why Is My Information Online?